Trontinemab (RG6102) is a monoclonal antibody developed by Genentech based on gantenerumab, an anti-amyloid monoclonal antibody. Compared to gantenerumab, it has 50 times as much penetrance into the brain.[1][2][3][4]
^Steenhuysen, Julie (2022-12-01). "Roche shutters most trials of Alzheimer's drug after failed trials". Reuters. Retrieved 2023-11-26.
^Zhang, Yun; Chen, Huaqiu; Li, Ran; Sterling, Keenan; Song, Weihong (30 June 2023). "Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future". Signal Transduction and Targeted Therapy. 8 (1): 248. doi:10.1038/s41392-023-01484-7. ISSN 2059-3635. PMC 10310781. PMID 37386015.
Trontinemab (RG6102) is a monoclonal antibody developed by Genentech based on gantenerumab, an anti-amyloid monoclonal antibody. Compared to gantenerumab...
tested with anti-amyloid monoclonal antibodies such as gantenerumab and trontinemab. Ruderisch, Nadine; Schlatter, Daniel; Kuglstatter, Andreas; Guba, Wolfgang;...